Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ARFGEF2
REST API REST API
Homo sapiens
ARFGEF2 is differentially expressed in 298 experiments: 123 organism parts: testis, bone marrow, ... (121 more);, 208 disease states: normal, control, ... (206 more);, 94 cell types 427 cell lines 34 compound treatments and 78 other conditions.
Synonyms BIG2
Orthologs ARFGEF2 (Bos taurus)   ENSCING00000002700 (Ciona intestinalis)   Arfgef2 (Rattus norvegicus)   ARFGEF2 (Gallus gallus)   ARFGEF2 (Danio rerio)   Arfgef2 (Mus musculus)   SEC7 (Saccharomyces cerevisiae)   ENSCING00000013872 (Ciona intestinalis)   ENSCING00000013871 (Ciona intestinalis)   sec71 (Drosophila melanogaster)   arfgef2 (Xenopus laevis)   ARFGEF2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, ARF guanyl-nucleotide exchange factor activity, cytoplasm, intracellular, membrane, Golgi membrane, vesicle-mediated transport, guanyl-nucleotide exchange factor activity, myosin binding, exocytosis, trans-Golgi network, binding, regulation of ARF protein signal transduction, GABA receptor binding, intracellular signal transduction
InterPro Term Sec7, DUF1981_SEC7_assoc
UniProt Accession Q9Y6D5, Q59FR3, F5H3H3
Gene-Disease Assocation HETEROTOPIA, PERIVENTRICULAR, AUTOSOMAL RECESSIVE
Search EB-eye ENSG00000124198
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (37 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-3529, E-GEOD-19639, E-GEOD-20081
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
WI38
2
E-MTAB-62, E-MTAB-37
HT1080
2
E-GEOD-20089, E-MTAB-37
BT-474
2
E-GEOD-5823, E-GEOD-3529
MDA468
2
E-MEXP-440, E-MTAB-62
421 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (54 experiments)

Factor Value U/D Experiments
1
2
E-TABM-145, E-TABM-130
monocyte
2
3
E-GEOD-995, E-GEOD-22373, E-MEXP-2019, E-GEOD-7307, E-GEOD-11755 ... (5 experiments)
CD8+ T cell
1
2
E-AFMX-5, E-TABM-145, E-GEOD-6740
intrathymic T progenitor cell
1
E-GEOD-1460
germ cell
1
E-MTAB-25
721 B lymphoblast
2
1
E-AFMX-5
88 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, ... (61 experiments)

Factor Value U/D Experiments
obesity
2
E-GEOD-2508, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
Classic-KS, HIV-, nodular (late) stage
2
E-MEXP-66, E-MTAB-62
astrocytoma
2
E-MTAB-37, E-GEOD-4290
Emery-Dreifuss muscular dystrophy
2
E-GEOD-3307, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
202 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-6907, E-GEOD-15205, E-GEOD-1417, ... (22 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-20719, E-GEOD-412, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (9 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
TGF
1
E-GEOD-15205
glucose
1
E-MEXP-941
camptothecin
1
E-GEOD-1417
CNOT7+CNOT8
1
1
E-MEXP-2218
28 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
53
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-MTAB-69, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-GEOD-21612, E-MEXP-2657, E-GEOD-22278, E-TABM-440, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (41 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-17636, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (10 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.459 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM